Subcommittee on Antifungal Susceptibility Tests – Disclosure Summary 2015

Personal, Professional, and Financial Interests

Relevant to the field(s) of work in which I would be involved with CLSI, I list below the organizations and activities with which I participate. For example, please list any controlling financial interest or benefit you may hold or have received including consulting fees or paid advisory boards, equity ownership/stock options or other information which your colleagues would need to know in order to fairly assess the basis of your position related to the CLSI activities.

Barbara D. Alexander, MD, MHS – Chairholder
Duke University Medical Center

Financial Interests or Benefits:
Research Grant or Contract: Astellas, Pfizer, Charles River Laboratories
Site investigator on a clinical trial: Viropharma, Astellas, Optimer

Mahmoud A. Ghannoum, MSc, PhD – Vice-Chairholder
Case Western Reserve University

Financial Interests or Benefits:
I have received grants/contracts, acted as an Advisor/Consultant, and I am on the Speakers’ Bureau for the following companies: Pfizer, Novartis, Astellas, Meiji, Viamet, and Great Lakes Pharma.

Members:

Mariana Castanheira, PhD
JMI Laboratories

Financial Interests or Benefits:
JMI Laboratories, Inc. has received research and educational grants in 2012-2014 from – Achaogen, Actelion, Affinium, American Proficiency Institute (API), AmpliPhi Bio, Anacor, Astellas, AstraZeneca, Basilea, BioVersys, Cardeas, Cempra, Cerexa, Cubist, Daiichi, Dipexium, Durata, Exela, Fedora, Forest Research Institute, Furiex, Genentech, GlaxoSmithKline, Janssen, Johnson & Johnson, Medpace, Meiji Seika Kaisha, Melinta, Merck, Methylgene, Nabriva, Nanosphere, Novartis, Pfizer, Polyphor, Rempex, Roche, Seachaid, Shionogi, Synthes, The Medicines Co., Theravance, ThermoFisher, Venatorx, Vertex, Waterloo, Wockhardt and some other corporations. Some JMI employees are advisors/consultants for Astellas, Cubist, Pfizer, Cempra, Cerexa-Forest, and Theravance. In regards to speakers bureaus and stock options-none to declare

Sharon Cullen
Siemens Healthcare Diagnostics, Inc.

Financial Interests or Benefits: Employee and stock owner of Siemens Healthcare Diagnostics which manufactures in vitro diagnostics tests and equipment including antimicrobial susceptibility tests and microbial identification tests. Note: Siemens Healthcare Diagnostics has announced the sale of the Microbiology Business Unit in which I am employed to Beckman Coulter.

Ana Espinel-Ingroff, PhD
Medical College of Virginia/VCU

Financial Interests or Benefits: None

Annette W. Fothergill., MA, MBA, MT(ASCP)
University of Texas Health Science Ctr.

Financial Interests or Benefits: None
Laura Kovanda
Astellas Pharma

Financial Interests or Benefits: Employee of Astellas Pharma Global Development, Inc.

Michael D. LaFleur, PhD
Arietis Corporation

Financial Interests or Benefits: Employee of Arietis Corporation

Shawn R. Lockhart, PhD, D(ABMM)
Centers for Disease Control and Prevention

Financial Interests or Benefits: None

Jacques F. Meis, MD, PhD
Canisius Wilhelmina Hospital, The Netherlands

Financial Interests or Benefits: Received grants from Astellas, Merck, and Pfizer. Consulting/Speaker: Consultant to Basileia and Merck, and received speaker’s fees from Merck and Gilead.

David S. Perlin, PhD
New Jersey Medical School-UMDNJ

Financial Interests or Benefits: Received grants funding from Astellas and Scynexis. Serve on advisory boards for Astellas, Merck, and Scynexis.

Nancy Wengenack, PhD
Mayo Clinic

Financial Interests or Benefits: None
Research grants or contracts: bioMérieux, Siemens, and ThermoFisher (TREK Diagnostics)

Peter R. Williamson, MD, PhD
National Institute of Health

Financial Interests or Benefits: None

Advisors:

David Andes, MD
University of Wisconsin

Financial Interests or Benefits: None
Research Grants - (Antifungal Pharmacodynamic Studies), Astellas, Merck, Novartis Advisor/Consultant- Pfizer, Merck

Lynette Berkeley, PhD
FDA Center for Drug Evaluation and Research

Financial Interests or Benefits: None

Philippe Dufresne, PhD
Institut national de santé publique du Québec

Financial Interests or Benefits: None
Research Grant: Pfizer investigator initiated research grant Advisor/Consultant: Collaborative project with bioMérieux for development of mass spectrometry for identification of fungi.
Kim Hanson, MD, MHS  
University of Utah and ARUP Laboratories

Financial Interests or Benefits: None

Cynthia C. Knapp, MS  
ThermoFisher Scientific

Financial Interests or Benefits: Employee of ThermoFisher Scientific

Pranab K. Mukherjee, PhD  
Case Western Reserve University

Financial Interests or Benefits:  
Consultant, Oasis Consumer Healthcare  
Consultant, ARMS Pharmaceutical LLC

Gary Procop, MD  
Cleveland Clinic

Financial Interests or Benefits: None

John H. Rex, MD, FACP  
AstraZeneca

Employee and shareholder of AstraZeneca Pharmaceuticals  
Non-Executive Director and shareholder of F2G Pharmaceuticals  
Consultant to Advent Life Sciences, an investor in F2G Pharmaceuticals

Ribhi Shawar, PhD, D(ABMM)  
FDA Ctr. for Devices/Rad. Health (CDRH)

Financial Interests or Benefits: None

Yvonne Shea, MS  
FDA Ctr. for Devices/Rad. Health (CDRH)

Financial Interests or Benefits: None

Maria Traczewski, BS, MT(ASCP)  
The Clinical Microbiology Institute

Financial Interests or Benefits: CMI has done business or is doing business with the following companies: AstraZeneca, Cubist, GlaxoSmithKline, Pfizer, Pfizer Animal Health, Bayer, Merck, Astellas, Theravance, Novartis, Paratek, Merck Animal Health, Elanco, Cardes, bioMerieux, Gilead, Intevet, Vertex, Cornerstone Therapeutics, Cerexa, Shering-Plough Vet. Division, MAP, APP, Novexel, Protez, Leo, Oscient, Achaogen, Trius, Replidyne, Bausch and Lomb, Blanca, Johnson & Johnson, Wyeth, Sanofi-Aventis, Dechra Pharmaceuticals, APP Pharmaceuticals, Symbiomix Therapeutics, Cepheid Inc., Siemens Healthcare Diagnostics, Advanced Food Technologies, Stanford University, Becton-Dickinson Company, and Basalia Pharmaceutica.

Kenneth G Van Horn, PhD, D(ABMM)  
Kindred Hospital

Financial Interests or Benefits: None
Nathan P. Wiederhold, PharmD  
University of Texas Health Science Center

Financial Interests or Benefits: Served as an investigator/received grant support from Astellas, bioMerieux, Dow Pharmaceutical Sciences, F2G, Medicis, Merck, Merz, Pfizer, Viamet

Scientific Advisory Board for Astellas, Merck, Pfizer, Toyama, Viamet

Sean Zhang, MD, PhD, D(ABMM)  
Johns Hopkins University

Financial Interests or Benefits: None
Research grants or contracts: IBIS Biosciences/Abbott Molecular